Privately-held PurMinds BioPharma (Burlington, Ontario, Canada) recently announced an investment in the psychedelic drug company IMIO Life Ltd., a subsidiary of Tel Aviv–based Nextage Therapeutics Ltd. (TASE:NXTG). Nextage Therapeutics is itself a division of the pharmaceutical company Nextar Chempharma Solutions (Ness Ziona, Israel). We reached out to PurMinds’ chief strategy and financial officer, Aron Buchman,…
San Diego company aiming to target glioblastoma with nanotechnology-based approach
The emerging biopharmaceutical company Global Cancer Technology (GCT; San Diego) is developing a novel x-ray–activated modality for drug delivery to treat glioblastoma, which remains stubbornly difficult to treat. GCT has a licensing agreement with the University of California, San Diego (UCSD) for a drug delivery platform that unites a nanocrystal to a prodrug that can be…